Hunter, Christopher A
Jones, Simon A
Article History
Received: 5 March 2015
Accepted: 19 March 2015
First Online: 21 April 2015
Change Date: 17 August 2017
Change Type: Corrigendum
Change Details: In the version of this article initially published, some of the labels in Figure 4a,b were incorrect. In Figure 4a, in the group of IL-6 blockers (top right), 'ALX-0061' should be removed and 'Siltuximab' and 'MEDI 5117' should be added, and in the group of IL-6R blockers (middle right), 'Siltuximab' and 'ALD518' should be removed and 'ALX-0061' should be added. In Figure 4b, in the group of inhibitors at bottom left, 'MEDI 5517' should be revised to 'MEDI 5117'. These errors have been corrected in the HTML and PDF versions of the article.
Change Date: 18 October 2017
Change Type: Erratum
Change Details: Nat. Immunol. 16, 448–457 (2015); published online 21 April 2015; corrected after print 17 August 2017 In the version of this article initially published, some of the labels in Figure 4a,b were incorrect. In Figure 4a, in the group of IL-6 blockers (top right), 'ALX-0061' should be removed and 'Siltuximab' and 'MEDI 5117' should be added, and in the group of IL-6R blockers (middle right), 'Siltuximab' and 'ALD518' should be removed and 'ALX-0061' should be added.
Competing interests
: S.A.J. has received funding support from Hoffman-La Roche, Ferring Pharmaceuticals and NovImmune and during the past 5 years has acted as an advisory consultant for Roche, Chugai Pharmaceuticals, NovImmune, Genentech, Sanofi Regeneron, Johnson & Johnson, Janssen Pharmaceuticals, Eleven Biotherapeutics and UCB. C.A.H. has received support from Amgen, Johnson & Johnson, and Janssen Pharmaceuticals, has acted as an advisory consultant for Medimmune and Biogen and is a member of the scientific advisory board of Surface Oncology.